ODAIA raises $15M Series C and makes Publicis health agency PHM its exclusive U.S. partner
Monograph Capital led the round for the Toronto company, which sells AI that tells drugmakers' sales and marketing teams which physicians to reach. PHM, part of Publicis Groupe, anchored the round and signed a platform agreement.

- Amount
- $15M
- Type
- Series C
- Company
- ODAIA
- Lead investor
- Monograph Capital
- Sector
- Health AI
- Announced
- Nov. 17, 2026
ODAIA sells drugmakers software that decides which physicians their sales reps and marketers should reach, and when. On Nov. 17 it added a unit of Publicis Groupe to both its investor list and its sales channel.
The Toronto company said it closed a $15 million Series C. Monograph Capital led it, and PHM, a U.S. health media agency that is part of Publicis Groupe, was the anchor investor. Investors from earlier rounds returned: BDC Capital, Flint Capital, Innospark Ventures and Graphite Ventures from the Series A, and Threshold Ventures and Wittington Ventures from the Series B. ODAIA did not disclose a valuation or its total funding.
Why it matters: Alongside the investment, ODAIA struck a platform deal naming PHM its sole agency partner in the U.S. The deal pairs a vendor of AI for pharma sales and marketing with a health media agency, and ODAIA says the tie-up will link what clients learn from digital media with what their sales reps learn in the field, so outreach to clinicians is planned across both. Philip Poulidis, ODAIA's chief executive and co-founder, said PHM would help the company reach more drugmakers more quickly.
What the product does
ODAIA says its platform combines a drugmaker's data, rep activity and digital engagement into one profile of each health care professional, shared by brand, marketing and field teams. Brand teams set their strategy once in a tool the company calls Brand Strategy Studio, and its decision engines translate that plan into specific calls on which clinicians to contact, by what route, at what moment and with what pitch, according to the company.
ODAIA says the software can flag doctors whose patients may soon need a given drug, in many cases months before a diagnosis appears in the records it analyzes. Its Field Intelligence product delivers prioritized call plans inside a rep's CRM, and Marketing Intelligence coordinates individual clinician outreach across digital and partner channels. Each recommendation shows the reasoning behind it, which ODAIA says lets commercial and compliance staff check it.
"Pharma has proven that AI works in commercial. The hard part now is scaling it," Poulidis said.
The investors
Monograph was a co-lead in ODAIA's Series B before leading this one, according to the announcement. "The ODAIA team has a track record of helping large and specialty pharma brands reach the physicians whose patients need their therapies most," said Charles Conn, a co-founder and partner at Monograph.
ODAIA started at the University of Toronto in 2018 and also has a Boston office. It said its customers range from top-20 global drugmakers to specialty companies, without naming any.
What comes next
The company said the money will go toward expanding its business with the large pharma customers it already has and toward further work on the platform. ODAIA will continue to sell directly to drug companies, and its software runs alongside each brand's existing CRM, analytics models and data systems, it said. The open questions are how many new pharma clients the PHM partnership brings in and whether ODAIA discloses customer counts or revenue as it grows.



